Coming Soon

A Study to Evaluate the Adverse Events and Efficacy of Telisotuzumab Adizutecan in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

The purpose of this study is to explore the safety and efficacy of a study drug called Telisotuzumab adizutecan (ABBV-400) in combination with existing therapies in Metastatic Colorectal Cancer (mCRC) patients.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Hanna Sanoff
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Colorectal)

IRB Number

24-3178

ClinicalTrials.gov

NCT06820463

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.